Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported updated Phase 1/2 clinical trial data for its antibody drug conjugate CRB-701, showing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE